SCOTTSDALE, AZ--(Marketwire - Oct 15, 2012) - Grant Walsh, Chairman of Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), which originated and is currently marketing the FDA-approved Prolieve® System in addition to the developing the APA-1000 that uses focused and controlled microwave energy to shrink or eradicate cancerous tumors with minimal invasion, has been interviewed on the Stock Legends Radio Show. Those interested in listening to the interview are encouraged to listen by visiting http://www.stocklegends.com/mdfzf/.
In addition to being the Chairman of Medifocus, Grant B. Walsh, 59, is the managing partner and Chief Executive Officer of EC Murphy Walsh, a management consulting firm specializing in performance improvement in service, healthcare and health related organizations. EC Murphy Walsh is based in Burlington, Ontario and also has offices in Amherst, New York. Prior to establishing EC Murphy Walsh, Mr. Walsh was the President and Chief Executive Officer of St. Peter's Health System in Ontario, Canada, a regional provider of integrated healthcare services. Previously, Mr. Walsh was an Executive regional provider of integrated healthcare services. Mr. Walsh holds a BA in English and Philosophy from Roberts Wesleyan College and an MBA from Southern Illinois University and has also pursued specialized study at Harvard University, McMaster University, St. Louis University, Cornell University and the State University of New York at Buffalo. Mr. Walsh is an Adjunct Professor in the Executive Education program at the DeGroote School of Business, McMaster University and has received from the DeGroote School of Business and the Conference Board of Canada the designation as a Chartered Director. Mr. Walsh has and does serve on numerous boards of directors.
About Stock Legends
At Stock Legends, we utilize newsletters, investor groups, message boards, chat rooms and social networking to accomplish the final goal which is bringing micro-cap public companies into the spot light to the investment community.
About Medifocus Inc.
Medifocus Inc. owns a patented microwave focusing technology platform (the Adaptive Phased Array ("APA") technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumor sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer. With the acquisition of Prolieve®, Medifocus now owns, in addition, a revenue generating commercial BPH heat treatment product generating cash flow to support the development and commercialization of other catheter based or APA based external focused heat systems for targeted thermotherapy of deep seated tumors anywhere in the body.
Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.